Like CJC-1295, this peptide is a growth hormone-releasing hormone analog
Reported, but not confirmed in a controlled study Important limits Frequency, dose link, and cause are unknown
A Doral provider explains how it works, candidacy, how many sessions to plan for, recovery, and how it compares to chin filler and surgery
FDA's evaluation concluded that the criteria weighed against placement on the list, citing inadequate physicochemical characterization, immunogenicity concerns from impurities and aggregates, lack of clinical effectiveness data for any approved use, and absence of published human exposure data for the proposed subcutaneous and topical routes
AOD-9604 has more clinical data behind it, including human trials and FDA GRAS status